Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 12, Pages 2784-2790Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2016.1167205
Keywords
BCL2; diffuse large B-cell lymphoma; double-expressor lymphoma; high-dose chemotherapy; MYC
Categories
Funding
- Chugai Pharmaceutical Co. Ltd
- Kyowa Hakko Kirin Co., Ltd
- Bristol-Myers K.K.
- Shionogi Co.
- Nippon Kayaku Co.
Ask authors/readers for more resources
Co-expression of MYC and BCL2 proteins in diffuse large B-cell lymphoma (DLBCL), or 'double-expressor lymphoma' (DEL), results in poor patient prognosis, but the significance of DEL when aggressive treatments are applied remains uncertain. We performed a retrospective analysis of 40 patients with de novo DLBCL, who were categorized as being at high/high-intermediate risk according to the age-adjusted International Prognostic Index. Patients underwent an R-Double CHOP regimen, a dose-intensified immunochemotherapy with or without consolidative high-dose chemotherapy followed by autologous stem cell transplantation. According to immunohistochemical analysis, 10 (25%) patients were categorized as having DEL, showing positivity for MYC (>= 40%) and BCL2 (>= 50%). The 3 year progression-free survival and overall survival of the DEL group were significantly worse compared with those of the non-DEL group (30% vs. 63%, p=0.019 and 40% vs. 82%, p=0.006, respectively). These results suggest that advanced DEL may need discrete treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available